by The RxPx Team | Sep 8, 2026 | Articles
For specialty therapies, adherence is rarely determined by a medication reminder alone. It is shaped by everything that happens around treatment: how quickly patients get started, whether they understand what to expect, how emerging barriers are identified, and... by The RxPx Team | Sep 1, 2026 | Articles
The most successful pharmaceutical launches don’t begin at approval. They begin when there’s still time to identify, and engineer out, preventable risk. By the time a therapy reaches Phase III clinical trials, it has progressed through years of clinical... by The RxPx Team | Aug 19, 2026 | Articles
FOR IMMEDIATE RELEASE RxPx Accelerates Growth with Leadership Expansion as AI-Powered Patient Safety and Support Platform Demonstrates Significant Gains in Adherence and Speed to Therapy Leadership expansion, strategic pharmaceutical partnerships and platform... by The RxPx Team | Jul 17, 2026 | Articles
Every pharmaceutical launch is measured against ambitious commercial forecasts. Brand teams spend years preparing for approval, market access, and physician uptake. Pharma invests upwards of $1-2 billion and 10+ years to bring a therapy to market. Yet once approved,... by The RxPx Team | Jul 7, 2026 | Articles
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust? That was the central question explored during Medicines Australia’s recent webinar, Conversations & The Code: Compliance and Decision Making – Navigating AI and Emerging... 
by The RxPx Team | May 26, 2026 | Articles
At Asembia AXS26, one message surfaced repeatedly across conversations with manufacturers, specialty pharmacies, hubs, and patient support leaders: healthcare fragmentation is becoming impossible to ignore. Disconnected systems, siloed vendors, fragmented patient... 